139 related articles for article (PubMed ID: 25521357)
1. Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab.
Allegrini G; Coltelli L; Orlandi P; Fontana A; Camerini A; Ferro A; Cazzaniga M; Casadei V; Lucchesi S; Bona E; Di Lieto M; Pazzagli I; Villa F; Amoroso D; Scalese M; Arrighi G; Molinaro S; Fioravanti A; Finale C; Triolo R; Di Desidero T; Donati S; Marcucci L; Goletti O; Del Re M; Salvadori B; Ferrarini I; Danesi R; Falcone A; Bocci G
Pharmacogenomics; 2014 Dec; 15(16):1985-99. PubMed ID: 25521357
[TBL] [Abstract][Full Text] [Related]
2. A pharmacogenetic interaction analysis of bevacizumab with paclitaxel in advanced breast cancer patients.
Coltelli L; Allegrini G; Orlandi P; Finale C; Fontana A; Masini LC; Scalese M; Arrighi G; Barletta MT; De Maio E; Banchi M; Fini E; Guidi P; Frenzilli G; Donati S; Giovannelli S; Tanganelli L; Salvadori B; Livi L; Meattini I; Pazzagli I; Di Lieto M; Pistelli M; Casadei V; Ferro A; Cupini S; Orlandi F; Francesca D; Lorenzini G; Barellini L; Falcone A; Cosimi A; Bocci G
NPJ Breast Cancer; 2022 Mar; 8(1):33. PubMed ID: 35314692
[TBL] [Abstract][Full Text] [Related]
3. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.
Schneider BP; Wang M; Radovich M; Sledge GW; Badve S; Thor A; Flockhart DA; Hancock B; Davidson N; Gralow J; Dickler M; Perez EA; Cobleigh M; Shenkier T; Edgerton S; Miller KD;
J Clin Oncol; 2008 Oct; 26(28):4672-8. PubMed ID: 18824714
[TBL] [Abstract][Full Text] [Related]
4. Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer.
Pentheroudakis G; Kotoula V; Kouvatseas G; Charalambous E; Dionysopoulos D; Zagouri F; Koutras A; Papazisis K; Pectasides D; Samantas E; Dimopoulos MA; Papandreou CN; Fountzilas G
Clin Breast Cancer; 2014 Oct; 14(5):330-8. PubMed ID: 24703319
[TBL] [Abstract][Full Text] [Related]
5. Genetic interaction of P2X7 receptor and VEGFR-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patients.
Solini A; Simeon V; Derosa L; Orlandi P; Rossi C; Fontana A; Galli L; Di Desidero T; Fioravanti A; Lucchesi S; Coltelli L; Ginocchi L; Allegrini G; Danesi R; Falcone A; Bocci G
Oncotarget; 2015 Oct; 6(30):28743-54. PubMed ID: 26337470
[TBL] [Abstract][Full Text] [Related]
6. Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer.
Gampenrieder SP; Hufnagl C; Brechelmacher S; Huemer F; Hackl H; Rinnerthaler G; Romeder F; Monzo Fuentes C; Morre P; Hauser-Kronberger C; Mlineritsch B; Greil R
Pharmacogenomics J; 2017 Jul; 17(4):344-350. PubMed ID: 27139155
[TBL] [Abstract][Full Text] [Related]
7. Clinical genotyping and efficacy outcomes: exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancer.
Pallaud C; Reck M; Juhasz E; Szima B; Yu CJ; Burdaeva O; Orlov S; Hilton M; Archer V; Mok T
Lung Cancer; 2014 Oct; 86(1):67-72. PubMed ID: 25154982
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
von Minckwitz G; Puglisi F; Cortes J; Vrdoljak E; Marschner N; Zielinski C; Villanueva C; Romieu G; Lang I; Ciruelos E; De Laurentiis M; Veyret C; de Ducla S; Freudensprung U; Srock S; Gligorov J
Lancet Oncol; 2014 Oct; 15(11):1269-78. PubMed ID: 25273342
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
Lang I; Brodowicz T; Ryvo L; Kahan Z; Greil R; Beslija S; Stemmer SM; Kaufman B; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Messinger D; Zielinski C;
Lancet Oncol; 2013 Feb; 14(2):125-33. PubMed ID: 23312888
[TBL] [Abstract][Full Text] [Related]
10. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
[TBL] [Abstract][Full Text] [Related]
11. Genetic interaction analysis of VEGF-A rs3025039 and VEGFR-2 rs2071559 identifies a genetic profile at higher risk to develop nodular goiter.
Molinaro A; Orlandi P; Niccolai F; Agretti P; De Marco G; Ferrarini E; Di Cosmo C; Vitti P; Piaggi P; Di Desidero T; Bocci G; Tonacchera M
J Endocrinol Invest; 2020 Feb; 43(2):149-155. PubMed ID: 31376092
[TBL] [Abstract][Full Text] [Related]
12. First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study.
Aogi K; Masuda N; Ohno S; Oda T; Iwata H; Kashiwaba M; Fujiwara Y; Kamigaki S; Ito Y; Ueno T; Takashima S
Breast Cancer Res Treat; 2011 Oct; 129(3):829-38. PubMed ID: 21805309
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.
Cameron D; Brown J; Dent R; Jackisch C; Mackey J; Pivot X; Steger GG; Suter TM; Toi M; Parmar M; Laeufle R; Im YH; Romieu G; Harvey V; Lipatov O; Pienkowski T; Cottu P; Chan A; Im SA; Hall PS; Bubuteishvili-Pacaud L; Henschel V; Deurloo RJ; Pallaud C; Bell R
Lancet Oncol; 2013 Sep; 14(10):933-42. PubMed ID: 23932548
[TBL] [Abstract][Full Text] [Related]
14. Association of IL-8 and eNOS polymorphisms with clinical outcomes in bevacizumab-treated breast cancer patients: an exploratory analysis.
Di Salvatore M; Lo Giudice L; Rossi E; Santonocito C; Nazzicone G; Rodriquenz MG; Cappuccio S; Inno A; Fuso P; Orlandi A; Strippoli A; Capoluongo E; Astone A; Cassano A; Barone C
Clin Transl Oncol; 2016 Jan; 18(1):40-6. PubMed ID: 26141413
[TBL] [Abstract][Full Text] [Related]
15. Race to report: are vascular endothelial growth factor genetic polymorphisms associated with outcome in advanced breast cancer patients treated with Paclitaxel plus bevacizumab?
Tan MH; Tan CS; Lim WY
J Clin Oncol; 2009 Mar; 27(8):1342; author reply 1342-3. PubMed ID: 19188671
[No Abstract] [Full Text] [Related]
16. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial.
Van Cutsem E; de Haas S; Kang YK; Ohtsu A; Tebbutt NC; Ming Xu J; Peng Yong W; Langer B; Delmar P; Scherer SJ; Shah MA
J Clin Oncol; 2012 Jun; 30(17):2119-27. PubMed ID: 22565005
[TBL] [Abstract][Full Text] [Related]
17. Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis.
Coltelli L; Allegrini G; Orlandi P; Giuntini N; Alì G; Fioravanti A; Bona E; Barletta MT; Fontanini G; Del Tacca M; Danesi R; Falcone A; Bocci G
Pharmacogenomics; 2009 Aug; 10(8):1225-9. PubMed ID: 19663667
[TBL] [Abstract][Full Text] [Related]
18. Impact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomy.
Berardi R; Brunelli A; Pagliaretta S; Paolucci V; Conti A; Goteri G; Refai M; Pompili C; Marcantognini G; Morgese F; Ballatore Z; Savini A; De Lisa M; Caramanti M; Santoni M; Zizzi A; Piva F; Mazzanti P; Onofri A; Sabbatini A; Scarpelli M; Cascinu S
Oncotarget; 2015 Aug; 6(22):19305-15. PubMed ID: 26254278
[TBL] [Abstract][Full Text] [Related]
19. First-line bevacizumab-paclitaxel in 220 patients with metastatic breast cancer: results from the AVAREG study.
Dank M; Budi L; Piko B; Mangel L; Erfan J; Cseh J; Ruzsa A; Landherr L
Anticancer Res; 2014 Mar; 34(3):1275-80. PubMed ID: 24596372
[TBL] [Abstract][Full Text] [Related]
20. Single-nucleotide polymorphisms in the vascular endothelial growth factor pathway and outcomes of patients treated with first-line cytotoxic chemotherapy combined with bevacizumab for advanced colorectal cancer.
Sohn BS; Park SJ; Kim JE; Kim KP; Hong YS; Suh C; Kim YS; Kim SY; Im SA; Kim SY; Kim JH; Ahn JB; Park YS; Kim TW
Oncology; 2014; 87(5):280-92. PubMed ID: 25139485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
